

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF:

Hidenori OHKI ET AL.

SERIAL NO: 09/248,267

FILED: FEBRUARY 11, 1999

FOR: CYCLIC HEXAPEPTIDES HAVING  
ANTIBIOTIC ACTIVITY

:

: GROUP ART UNIT: 1653

: EXAMINER: DAVENPORT

:

AMENDMENT UNDER 37 C.F.R. 1.312(a)

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Responsive to the Raw Sequence Listing Error Report received May 24, 2000,  
Applicants request prompt entry of the amended sequence listing provided herewith. As the  
issue fee has not yet been paid, Applicants respectfully request that the Examiner enter this  
amended sequence listing pursuant to Rule 312(a).

REMARKS

The amended sequence listing attached herewith is provided to comply with the new  
sequence rule requirements. The amendment to the sequence listing is fully supported by the  
disclosure as originally filed and does not introduce new matter. The information on the  
paper copy and computer readable form of the sequence listing are identical. On May 25,  
2000 the Applicants consulted with Mark Spenser at STIC who indicated that the sequence  
listing would comply with the new sequence rules if residues 1 and 4 identified as "Xaa" are  
further described in the features section of the sequence listing. Accordingly, the features

#12  
Amended (32)  
5/17/01  
OK to  
enter  
5/22/01  
AMD